Trends of Antibacterial Resistance at the National Reference Laboratory in Cameroon: Comparison of the Situation between 2010 and 2017 by MASSONGO, M. et al.
Research Article
Trends of Antibacterial Resistance at the National Reference
Laboratory in Cameroon: Comparison of the Situation between
2010 and 2017
M. Massongo ,1,2 L. Ngando,1,3 E. W. Pefura Yone,1,2 Ariane NZouankeu,2 W. Mbanzouen,3
M. C. Fonkoua,4 A. Ngandjio,4 J. Tchatchueng,4 D. Barger,5 and M. C. Tejiokem4
1Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1, Yaoundé, Cameroon
2Jamot Hospital, Yaoundé, Cameroon
3Bacteriology Unit, Cameroon Pasteur Centre, Member of Institut Pasteur International Network, Yaoundé, Cameroon
4Epidemiology and Public Health Unit, Cameroon Pasteur Centre, Member of Institut Pasteur International Network,
Yaoundé, Cameroon
5Bordeaux School of Public Health (ISPED), University of Bordeaux, Inserm 1219 Bordeaux Population Health, Bordeaux, France
Correspondence should be addressed to M. Massongo; massongo.massongo@fmsb-uy1.cm
Received 24 March 2021; Revised 28 April 2021; Accepted 11 May 2021; Published 24 May 2021
Academic Editor: Khalid Mehmood
Copyright © 2021 M. Massongo et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Introduction. Antimicrobial resistance represents a growing public health threat. One of the World Health Organization’s strategic
objectives is “strengthening knowledge through surveillance and research.” Sub-Saharan African countries are still far from
achieving this objective. We aimed to estimate and compare the prevalence of antibacterial resistance in 2010 and 2017 in
Cameroon. Methods. We conducted a retrospective study on all clinical specimens cultured in Centre Pasteur du Cameroun
(CPC) in 2010 and 2017. Data were extracted from the CPC’s laboratory data information system software and then managed
and analyzed using R. Bacterial resistance rates were calculated in each year and compared using chi-square or Fisher’s tests,
and relative changes were calculated. Outcomes included acquired resistance (AR), WHO priority resistant pathogens, some
specific resistances of clinical interest, and resistance patterns (multi, extensively, and pan drug resistances) for five selected
pathogens. Results. A total of 10,218 isolates were analyzed. The overall AR rate was 96.0% (95% CI: 95.4–96.6). Most of WHO
priority bacterial resistance rates increased from 2010 to 2017. The most marked increases expressed as relative changes
concerned imipenem-resistant Acinetobacter (6.2% vs. 21.6%, +248.4%, p = 0:02), imipenem-resistant Pseudomonas aeruginosa
(13.5% vs. 23.5%, +74.1%, p < 0:01), 3rd generation-resistant Enterobacteriaceae (23.8% vs. 40.4%, +65.8%, p < 10−15),
methicillin-resistant Staphylococcus aureus (27.3% vs. 46.0%, +68.6%, p < 0:002), fluoroquinolone-resistant Salmonella (3.9% vs.
9.5%, +142.9%, p = 0:03), and fluoroquinolone-resistant Enterobacteriaceae (32.6% vs. 54.0%, +65.8%, p < 10−15). For selected
pathogens, global multidrug resistance was high in 2010 and 2017 (74.9% vs. 78.0% +4.1%, p = 0:01), intensively drug resistance
rate was 5.8% (7.0% vs. 4.7%; p = 0:07), and no pan drug resistance has been identified. Conclusion. Bacterial resistance to
antibiotics of clinical relevance in Cameroon was high and appeared to increase between 2010 and 2017. There is a need for
regular surveillance of antibacterial resistance to inform public health strategies and empirically inform prescription practices.
1. Background
Antimicrobial resistance (AMR) has increased within the
past years, and according to the World Health Organization
(WHO), this is a growing threat for public health worldwide
that calls for urgent and global measures [1]. Although AMR
is a natural phenomenon, human factors have a significant
impact on its spread. Such factors can be behavioral (inade-
quate use of antimicrobials, lack of hygiene), structural
(weakness in laboratory supply), or managerial (lack of sur-
veillance, inadequate or lacking control programs, poor reg-
ulation) [2]. Inadequate use of antimicrobials is one of the
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major AMR suppliers. This includes antibiotic adds in drink-
ing water and daily feed of food-producing animals [3], as
well as the intensive use of growth promoters that can
encourage the growth of selected resistant bacteria [4]. The
overuse, subtherapeutic, or other misuse of antibiotics in ani-
mals has shown a correlation with the occurrence of resistant
bacteria in humans. These resistant bacteria range from
Escherichia coli to Mycobacterium bovis [5–8]. Some factors
are more likely to occur in low income countries, such as lim-
ited access to a right diagnosis or illicit drug to sell and use,
among others [9]. Unregulated antimicrobial use and nones-
timation of annual usage are also frequent in developing
countries, as shown by Rahman in Pakistan [10].
Facing this growing threat, the WHO published in 2014 a
global report on antimicrobial resistance surveillance [11].
Based on national, regional, and global data, this report
revealed the sanitary and economic impact of AMR, which
included among others: a twofold increase of all-cause mor-
tality rate, an increased risk of infection after admission in
intensive care unit, an increased hospitalization stay, an
increased frequency of septic shock, and a significant increase
of management cost. For many sub-Saharan African (SSA)
countries including Cameroon, the expressions “No informa-
tion obtained for this report” or “No national data available”
occured in this first report. At that time, studies on AMR in
Cameroon were scarce and old. They were limited in terms
of geographical areas and pathogens. However, they showed
an increasing AMR rate between the 1990s and the late
2000s [12–15]. One year later, WHO published a country
situation analysis of the response to AMR [2], based on a 2-
year survey with the national sanitary authorities of state
members. Only 8 SSA countries (Africa WHO region) out
of 47 (17.0%) provided data for this report, while 127/147
(85.0%) responded for the other WHO regions. African
countries showed a lack of national AMR policies, lack of
sensitization programs, and inappropriate use of antimicro-
bials, among others. There was no data from Cameroon in
this second report.
After those 2 baseline documents, WHO published in
2016 its Global Action Plan on antimicrobial resistance,
based on 5 strategic objectives. The objective number 2 was
“to strengthen the knowledge and evidence base through sur-
veillance and research” [16]. We aimed to provide data on
the recent evolution of AMR in Cameroon, pursuing a dual
purpose: public health (contributing to the objective number
2 of WHO’s Global Action Plan) and clinical (possible impli-
cations on antibiotics protocols).
2. Materials and Methods
2.1. Study Design and Settings.We performed a retrospective
study from April 4 to June 1, 2018, in Centre Pasteur du
Cameroun (CPC), Yaoundé, the national reference labora-
tory in biology and public health, and Member of the Pasteur
Institute International Network. As a nationwide reference
laboratory, CPC analyzes specimen coming from Yaoundé
and other regions of the country.We analyzed bacteriological
routine data, collected during two distinct one-year periods
(2010 and 2017), and stored in the laboratory data informa-
tion system (GLIMS). We initially aimed to perform an up-
to-date ten-year comparison (2007–2017) of the various
AMR features targeted, 2017 being the more recent year with
completed data. Unfortunately, GLIMS was put in place in
July 2009, making 2010 the first year with comprehensive
stored data.
2.2. Study Population and Sampling. All bacterial analyses
with a valid susceptibility test conducted in CPC in 2010
and 2017 were considered for this study, regardless of their
collection site or source of specimens (blood, sputum, urine,
stool, pus, etc.). The following were excluded from analysis:
samples with isolates from nonpathological swabs (including
systematic research with no clinical interest), fungal speci-
men, or duplicates, especially for the Mycoplasma family,
since both Mycoplasma hominis and Ureaplasma urealyti-
cum were systematically reported when one of them was
identified (Figure 1).
2.3. Biological Analysis: Procedures and Interpretation. Bio-
logical samples had been collected at or transferred to CPC
during the enrollment period. For each sample, the name,
age, and gender were used to label the corresponding samples
and create ID codes for each analysis. Samples were then
brought to the bacteriology lab for analysis. Most of the spec-
imen were examined using light microscopy after Gram
staining or other appropriate method to assess the presence
of pathogens. Blood specimens were incubated at 37°C in
BactALERT 3D Automaton (Biomerieux) and examined
daily for evidence of bacterial growth. When needed, speci-
mens were cultured according to French microbiology guide-
lines [17, 18]. Bacteria identification was done using Vitek 2
Compact (Biomerieux) automaton and API kits. The antibi-
otics susceptibility tests were performed using standard
methods (disk, e-test, liquid medium for Vitek 2 from Janu-
ary 2014). Reference documents for these tests were the
CASFM (Comité Antibiogramme de la Société Française de
Microbiologie) 2010 and 2016 [19, 20]. Results were stored
in GLIMS using generated ID codes in tables including
patient identification (name, age, gender), sample type or
source, microorganism, and susceptibility profile. The later
was given through 3 modalities: susceptible (S), intermediate
(I), or resistant (R).
2.4. Data Management and Analysis. From GLIMS, we
extracted all bacteriology analysis stored in 2010 and 2017
into Excel® tables without patients’ name. The crude global
database underwent the abovementioned filters (Figure 1).
The resulting table was then uploaded to R version 3.4.3,
for data management and analysis. Variables were renamed
and harmonized, and new variables were created to fit with
our 3 main outcomes:
(i) Global Acquired Resistance. The susceptibility pro-
file was processed to obtain a binary variable
(absence or presence of acquired resistance). There
was no acquired resistance (wild strain) if a given
bacterium was still fully susceptible (S) to all antibi-
otics (ATB) naturally active in vitro. There was
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acquired resistance (resistant strain) if the pathogen
had been found intermediate (I) or resistant (R) for
at least one of these ATBs
(ii) Specific Resistance. This informed susceptibility pro-
file of the bacterium regarding a given ATB and per-
mitted identification of WHO’s antibiotic-resistant
“priority pathogens.” These are 12 families of bacte-
ria that pose the greatest threat to human health,
divided into three categories according to the urgency
of the need for new antibiotics: critical (priority 1),
high (priority 2), and medium (priority 3) [21]
(iii) Resistance Pattern. It is applied to Enterobacteria-
ceae, P aeruginosa, A baumannii, Staphylococcus
aureus, and Enterococcus spp, which are frequently
involved in healthcare-associated infections. For
these bacteria, 5 resistance levels were defined by
an international expert proposal from the Centre
for Disease Control (CDC) and the European Centre
for Disease Control (ECDC): wild, acquired resistant
(AR), multidrug-resistant (MDR), extensively drug-
resistant (XDR), and pan drug-resistant (PDR) bac-
teria [22]. Wild and resistant bacteria were defined
as stated in the variable “susceptibility profile.”
MDR was defined as acquired nonsusceptibility to
at least one agent in three or more antimicrobial cat-
egories. XDR was identified when a bacterial isolate
remained susceptible to only one or two ATB cate-
gories. PDR was defined as nonsusceptibility to all
agents in all antimicrobial categories [22]
For each of these outcomes, the corresponding AMR
indicators for a given bacterium or group of bacteria were
estimated in 2010 and 2017, using the following formula:
Prevalence =
Number of isolates presenting the given resistance
Total number of isolates concerned
× 100:
ð1Þ
A relative change (RC) from 2010 to 2017 was then calcu-
lated using the following formula:
RC =
Prevalence in 2017 − Prevalence in 2010
Prevalence in 2010
× 100: ð2Þ
The global prevalence of antibacterial resistance was pre-
sented with its 95% confidence interval. The specific AMR
rates were given as numbers and percentages. Between-
period comparisons were performed using Chi square or
Fisher tests. A p value <0.05 was considered as significant.
2.5. Ethical Statements. This work was approved by CPC’s
administrative board. Since data had been collected routinely
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Figure 1: Flow chart of isolate inclusion in the study on antibacterial resistance, Centre Pasteur du Cameroon, 2010 and 2017, Yaoundé,
Cameroon.
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personal contact details were not available, individual con-
sents could not be obtained from participants. Data were
analyzed anonymously. The study induced no risk for
patients or CPC staff.
3. Results
3.1. Study Population, Specimens, and Bacterial Isolates. A
total of 55,144 analysis were extracted; 48.2% of them were
realized from 2017. Analyses resulting from systematic
demands or screening purpose (such as beta hemolytic strep-
tococci in throat, Escherichia, Campylobacter, and other
entero-pathogens in stool, Candida in stool and vaginal fluid,
nasal or throat staphylococci, and vaginal streptococcus B)
were first excluded, since they did not reflect a clinical infec-
tious situation, and most of them had negative results (which
were systematically reported and stored). These 37,511 anal-
yses accounted for 2/3 of the total. Nonbacterial isolates
(mainly fungi) were then excluded, followed by bacterial
one for which the identification was imprecise or not com-
pleted (such as “Gram-negative bacillus,” “Gram-positive
bacteria,” and “Other staphylococcus”). Lastly, duplicates of
Mycoplasmas (Mycoplasma hominis and Ureaplasma urealy-
ticum) were eliminated. These duplicates appeared for some
isolates and consisted in a second line for the same patient
and the same specimen but without any susceptibility test.
This selection process led to a final sample of 10,218 isolates
(Figure 1).
These isolates originated from 7,314 patients, 3,394
(46.4%) enrolled in 2010, and 3,920 (53.6%) in 2017. Their
mean age ± standard deviation was 30:2 ± 21:0 years, nearly
75% of them were adults, and 62.6% were woman. There
were 8,985 distinct specimens, from 23 different collection
sites. The collection sites were dominated by female genital
(32.7%) and urinary (28.7%) ones. These samples were gath-
ered into 4 groups, according to their origin and clinical rel-
evance. Comparison between 2010 and 2017 according to
patients’ gender and age as well as collection sites is shown
in Table 1.
A total of 71 bacteria species were identified and grouped
into 14 categories, according to morphological and suscepti-
bility criteria (Table 2). Genital Mycoplasma accounted for
one-third of the total. Apart from those genital tract com-
mensals, Escherichia coli (17.0%), Klebsiella pneumoniae
(8.2%), and Staphylococcus aureus (5.0%) were the 3 more
frequent bacteria identified in this study.
3.2. Global Acquired Resistance. Of the 10,218 bacterial iso-
lates, 5,405 (52.8%) underwent a proper acquired resistance
estimation. The other were excluded mainly due to missing
or discordant data in the susceptibility tests (45.9%) and in
a few cases for insignificant number (1.3%).
Among these 5,405 isolates, 5,189 were resistant to at
least one antibiotic usually active in vitro, giving an overall
prevalence (95% CI) of acquired resistance in this bacterial
population of 96.0% (95.4–96.6)%. This prevalence increased
from 2010 to 2017 (92.8% to 99.2%, RC = +6:9%, p < 0:0001).
Four bacterial groups, accounting for 75.3% of the total, had a
100% acquired resistance rate in 2010 and 2017. These were
Enterobacteriaceae, other fermenting GNB, Enterococci,
and Anaerobic (Table 3). In addition, Streptococcus pneumo-
niae (56 isolates), Pseudomonas aeruginosa (195 isolates),
and Acinetobacter spp (150 isolates) also had a 100% resis-
tance rate at the two data collecting periods.
3.3. Specific Resistances.Globally, an increase inWHOpriority
resistances was observed between 2010 and 2017, with relative
changes ranging from +32.4% (Ampicillin-R Haemophilus
influenzae) to +248.4% (Imipenem-R Acinetobacter bauman-
nii). Only imipenem-resistant Enterobacteriaceae were less
frequent in 2017 than 2010 (RC of -10.8%). For an unknown
reason, fluoroquinolones (FQ) susceptibility was not tested
Table 1: Collection sites distribution, concerning bacterial analysis in 2010 and 2017, Centre Pasteur du Cameroon, Yaounde. Continuous
data are expressed in counts ± standard deviation and categorical data in counts (frequencies in %).
Variable Modalities Overall 2010 2017 p value
Sex∗
N = 7,588
Female 4,748 (62.6) 2,274 (63.4) 2,474 (61.9) 0.187
Male 2,840 (37.4) 1,315 (36.6) 1,525 (38.1)
Total 7,588 (100.0) 3,589 (100.0) 3,999 (100.0)
Age∗
N = 7,711
Mean 30:2 ± 21:0 29:2 ± 20:0 31:1 ± 22:0 <0.001
Adult (>18 years) 5,742 (74.5) 2,684 (74.9) 3,058 (74.0) 0.343
Teen/child (≤18) 1,969 (25.5) 897 (25.1) 1,072 (26.0)
Total 7,711 (100.0) 3,581 (100.0) 4,130 (100.0)
Specimen group∗∗
N = 8985
Deep 4,350 (48.4) 2,012 (48.1) 2,238 (48.7) 0.280
Female genital 3,290 (36.6) 1,525 (36.4) 1,765 (36.8)
Male genital 711 (7.9) 332 (7.9) 379 (7.9)
Superficial 634 (7.1) 319 (7.6) 315 (6.6)
Total 8,985 (100.0) 4,188 (100.0) 4,697 (100.0)
∗Sex and age were those informed on each collection site. Given the possibility for a patient to provide more than one sample, there were more samples than
patients. ∗∗Deep specimen included blood cultures, urine, stool, foreign bodies, soft tissue, broncho-pulmonary, bone-and-joints, pleural effusion, cerebrospinal
fluid, intraperitoneal, liver punctures, cerebral, lymph nodes, and gastric liquid. Superficial ones were skin, throat, nasal or wound swab, and any externalized
fluid.
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for Neisseria gonorrhoeae in 2010, but only in 2017. FQ-R
N gonorrhoeae had the highest rate (80.9%) among the 12
WHO priority pathogens in 2017. Three specific resis-
tances not observed in 2010 were present in 2017:
Vancomycin-resistant Enterococcus spp, 3rd generation ceph-
alosporin- (3GC-) resistant Neisseria gonorrhoeae, and
fluoroquinolone-resistant Shigella spp. Concerning other
pathogens and resistances, Mycoplasma resistance was high
and slightly increased for fluoroquinolones, while it decreased
for cyclins, between 2010 and 2017. There was a >100%
increase in 3GC-resistant Escherichia coli (Table 4).
3.4. Resistance Patterns. As mentioned in Material and
Methods, resistance pattern determination applied to Entero-
bacteriaceae, P aeruginosa, A baumannii, Staphylococcus
aureus, and Enterococcus spp. Overall, 4,903 (47.9%) strains
were eligible. Among these, 4,474 fulfilled the required cri-
teria, on which 3,422 (76.5%) were classified multidrug
resistance (MDR). Global resistance patterns and their
comparison between 2010 and 2017 are shown in Table 5.
No pan drug resistance (PDR) was identified. The
between-period comparison differed from one bacterium to
another. MDR increased distinctly for S. aureus, while it
tended to remain stable for the 4 other pathogens. Con-
versely, extensively drug resistance (XDR) increased very
highly for A. baumannii and decreased for the other patho-
gens, although most of the differences were not statistically
significant (Table 6).
4. Discussion
More than 10,000 antibiotic susceptibility tests were analyzed
in this study. Genital mycoplasmas were the most frequent
bacteria, followed by E. coli. Swabs were clinically relevant
for >90% of them. Almost 100% of strains had an acquired
resistance at baseline. All WHO priority resistances highly
Table 2: Bacterial groups identified in 2010 and 2017 in Centre Pasteur du Cameroun.
Bacterial group Isolates 2010 (%) Isolates 2017 (%) Over all (%)
Genital Mycoplamas 1,637 (34.8) 1,852 (33.6) 3,489 (34.1)
Group 1 Enterobacteriaceae 1,162 (24.7) 1,057 (19.2) 2,219 (21.7)
Staphylococci 375 (8.0) 669 (12.1) 1,044 (10.2)
Group 2 Enterobacteriaceae 456 (9.7) 469 (8.5) 925 (9.1)
Streptococci 319 (6.8) 321 (5.8) 640 (6.3)
Group 3 Enterobacteriaceae 225 (4.8) 301 (5.5) 526 (5.1)
Nonfermenting Gram-negative bacilli 221 (4.7) 273 (5.0) 494 (4.8)
Enterococci 126 (2.7) 287 (5.2) 413 (4.0)
Other Gram-negative bacilli 63 (1.3) 71 (1.3) 134 (1.3)
Gram-negative cocci 22 (0.5) 110 (2.0) 132 (1.3)
Other Gram-positive cocci 23 (0.5) 44 (0.8) 67 (0.7)
Vibrio cholerae 58 (1.2) 0 (0.0) 58 (0.6)
Gram-positive bacilli 3 (0.1) 36 (0.7) 39 (0.4)
Anaerobic 15 (0.3) 23 (0.4) 38 (0.4)
Total 4,705 (100.0) 5,513 (100.0) 10,218 (100.0)
Enterobacteriaceae resistance groups: Group 1 = no beta − lactamase, Group 2 = low − level penicillinase, Group 3 = low − level cephalosporinase.




Relative change p value
Isolates AR (%) Isolates AR (%) Isolates AR (%)
Enterobacteriacae 3,371 3,371 (100.0) 1,684 1,684 (100.0) 1,687 1,687 (100.0) 0.0 —
Nonfermenting GNB∗ 392 380 (96.9) 167 162 (97.0) 225 218 (96.9) -0.1 0.30
Other GNB 113 113 (100.0) 54 54 (100.0) 59 59 (100.0) 0.0 —
Staphylococci 419 330 (78.8) 266 183 (88.8) 153 147 (96.1) +39.7 <0.001
Streptococci 505 391 (77.4) 300 195 (65.0) 205 196 (95.6) +47.1 <0.001
Enterococci 408 408 (100.0) 126 126 (100.0) 282 282 (100.0) 0.0 —
Gram-negative cocci 124 123 (99.2) 15 15 (100.0) 109 108 (99.1) -0.9 1
Anaerobic 17 17 (100.0) 9 9 (100.0) 8 8 (100.0) 0.0 —
Vibrio cholerae 56 56 (100.0) 56 56 (100.0) 0 0 (0.0) — 1
Total 5,405 5,189 (96.0) 2,677 2,484 (92.8) 2,728 2,705 (99.2) +6.9 <0.001
∗GNB: Gram-negative bacilli.
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increased between 2010 and 2017 except Imipenem-R
Enterobacteriaceae which slightly decreased. Three resis-
tances not seen in 2010 were present 2017 in this category
(Vancomycin-R Enterococcus spp, 3GC-R Neisseria gonor-
rhoeae, and Fluoroquinolone-R Shigella spp). The prevalence
of penicillin nonsusceptible S. pneumoniae was low but
increased between the 2 periods, while >50% ofH. influenzae
were initially ampicillin-R. FQ-R Enterobacteriaceae were
frequent in 2010 and almost doubled 7 years later. Less than
5% of genital mycoplasmas were still fully susceptible to FQ,
while the susceptibility to josamycine remained active for
nearly all of them. More than 75% of eligible strains were
MDR, and no PDR was identified.
Our sample size allowed relevant counts for most of bac-
teria of clinical interest. This size was higher than most of
those we found in other Cameroonian or African studies
Table 4: Some specific resistances of clinical interest as per WHO priority resistances and their relative change between 2010 and 2017,






















167 15.6 65 6.2 102 21.6 +248.4 0.032
Imipenem-R Pseudomonas
aeruginosa
234 18.4 119 13.5 115 23.5 +74.1 < 0.01
Imipenem-R Enterobacteriaceae 2,066 3.5 504 4.0 1,562 3.3 -17.5 < 10-8
3GC2-R Enterobacteriaceae 3,643 32.1 1,818 23.8 1,825 40.4 +69.8 < 10-15
WHO priority 2
Vancomycin-R Enterococcus spp 412 0.5 126 0.0 284 0.7 — 1
Methicillin-R Staphylococcus aureus 412 34.2 262 27.3 150 46.0 +68.6 < 10-3
Fluoroquinolone-R
Campylobacter spp
19 52.6 12 41.7 7 71.4 +71.4 0.3
Fluoroquinolone-R Salmonella spp 144 5.6 103 3.9 41 9.5 +142.9 0.03
3GC-R Neisseria gonorrhoeae 123 1.6 18 0.0 105 1.9 — 1
Quinolone-R Neisseria gonorrhoeae 18 16.7 18 16.7 0 — — —
Fluoroquinolone-R Neisseria
gonorrhoeae




84 5.9 56 5.2 28 7.6 +47.0 0.09
Ampicillin-R Haemophilus
influenzae
62 70.9 9 55.6 53 73.6 +32.4 < 0.01





3,447 45.1 1710 34.0 1737 56.0 +65.8 < 10-15
3GC-R Escherichia coli 1,720 25.9 880 17.1 840 35.2 +105.8 < 10-15
Fluoroquinolone-R Escherichia coli 1,693 49.9 867 37.4 826 61.6 +64.5 < 10-15
Fluoroquinolone-R Mycoplasmas 3,505 63.8 1,636 62.8 1,869 64.6 +1.8 < 10-3
Fluoroquinolone-I/R4 Mycoplasmas 3,505 97.6 1,636 98.6 1,869 96.8 -1.8 < 10-3
Cyclin-R Mycoplasmas 3,505 27.2 1,636 32.7 1,869 22.3 -31.8 < 10-13
Josamycin-R Mycoplasmas 3,505 1.10 1,636 1.1 1,869 1.2 +0.1 0.90





Numbers Rate, % Numbers Rate, % Numbers Rate, %
Wild 5 0.1 2 0.1 3 0.1 29.5 1.00
Acquired resistance 787 17.6 393 18.1 394 17.1 -5.4 0.43
Multidrug resistance 3422 76.5 1628 74.9 1794 78.0 4.1 0.01
Extensively drug resistance 260 5.8 152 7.0 108 4.7 -48.8 <0.01
Total 4474 100.0 2175 100.0 2299 100.0 0.0 —
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[12–14, 23, 24]. Age distribution of providing patients (74.5%
adults and 21:1% < 5 years) differed from the national one,
which shows less adults (53.9%) and more under 5 children
(30.5%) [25]. The high frequency of female genital swabs in
our sample could partly explain this gap. The predominance
of enterobacteria (and especially E. coli) in our sample is con-
sistent with the human bacterial pathogen’s distribution.
The very high prevalence of AR was predictable. This
high prevalence is now well documented and is one of the
reasons for global mobilization on AMR. Interestingly, bacte-
ria who scored a 100% AR rate in 2010 and 2017 are among
the most frequent human pathogens (Enterobacteriaceae and
other GNB). This also makes them the most exposed to anti-
biotic pressure (including inadequate use), which is thought
to be involved in resistance occurrence [26].
In our knowledge, few has been published on class 1WHO
priority resistance (especially Imipenem-R A baumannii,
Imipenem-R P aeruginosa, Imipenem-R Enterobacteriaceae)
in Africa. However, recent studies reported imipenem-R Pseu-
domonas aeruginosa (Ipm-R Pa) rate of 11% in Nigeria [27]
and 33% in Uganda [28], while we had 23.5% in 2017. An
older South African study found a 42% Ipm-R Pa rate in
2007 [29], quite higher than what we got. Comparable dispar-
ities were observed for Imp-R Acinetobacter baumannii. Such
disparities may be related to several factors such as drug poli-
cies, carbapenem availability, or financial access. These SSA
rates of Imp-R non fermenting GNB (NF GNB) were quite
higher than those observed in Western Europe in 2017-2018,
which were <10% [30–32]. However, they were still lower than
the Iranian 54% [33] and the 66 to 90% range found in Latin
America [34]. The rapid increase of Imp-R NF GNB in Cam-
eroon should lead to caution in antibiotic use, since there is no
alternative to face highly resistant bacteria in the country.
Carbapenem-R Enterobacteriaceae appeared to have a
low and stable frequency in our study. Higher values were
found inMorocco [35]. Our 3GC-R Enterobacteriaceae prev-
alence was lower than those found in earlier Cameroonian
studies, around 50% [12–14, 23, 36], probably due to sam-
pling disparities. Since our enrollment was more global
(including outpatients and hospitalized ones) than the one
in those studies (hospitalized patients only). We found no
study on Vancomycin-R enterococcus in Africa, which
appeared to be emerging in Cameroon. This may cause seri-
ous therapeutic issues. Methicillin-R Staphylococcus aureus
(MRSA) was more frequent in our study than in other SSA
recent studies, where its prevalence ranged from 0% in Zam-
bia to 7% in Zimbabwe [37–39]. This high prevalence may
compromise patient management, since the Cameroonian
minimum wage, 52.3 euros [40], cannot afford a daily dose
of vancomycin (unique anti-MRSA available in Cameroon).
Our FQ-R Campylobacter prevalence was also high com-
pared to other SSA series, ranging from 20 to 33% [41, 42].




Relative change p value
Overall 2010 2017
Enterobacteriaceae
AR 448 (13.2) 234 (13.7) 214 (12.7) -7.3%
0.09MDR 2,748 (81.1) 1,362 (79.8) 1,386 (82.4) +3.2%
XDR 193 (5.7) 110 (6.5) 83 (4.9) -23.4%
Total 3,389 (100.0) 1,706 (100.0) 1,683 (100) —
Pseudomonas aeruginosa
AR 54 (27.7) 25 (25.9) 29 (29.9) +15.5%
0.33MDR 109 (55.9) 53 (54.1) 56 (57.7) +6.7%
XDR 32 (16.4) 20 (20.4) 12 (12.4) -39.2%
Total 195 (100.0) 98 (100.0) 97 (100.0) —
Acinetobacter spp
AR 52 (34.7) 21 (37.5) 31 (33.0) -10.7%
0.44MDR 84 (56.0) 32 (57.1) 52 (55.3) -1.8%
XDR 14 (9.3) 3 (5.4) 11 (11.7) +116.7%
Total 150 (100.0) 56 (100.0) 94 (100.0) —
Enterococcus spp
AR 78 (19.2) 11 (8.7) 67 (23.8) +58.6%
< 10-7MDR 317 (77.9) 104 (82.6) 213 (75.8) -8.1%
XDR 12 (2.9) 11 (8.7) 1 (0.4) -95.4%
Total 407 (100.0) 126 (100.0) 281 (100.0) —
Staphylococcus aureus
Wild 5 (1.6) 2 (1.1) 3 (2.1) +90.9%
<0.001
AR 155 (46.6) 102 (54.0) 53 (36.8) -17.2%
MDR 164 (49.2) 77 (40.7) 87 (60.4) +48.4%
XDR 9 (2.7) 8 (4.2) 1 (0.7) -83.3%
Total 333 (100.0) 189 (100.0) 144 (100.0) —
AR: acquired resistance; MDR: multidrug-resistant; XDR: extensively drug-resistant; PDR: pan drug-resistant.
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Meanwhile, FQ-R Salmonella in 2010 close to 4.3% found one
year later in Congo [43]. The seven-year increase (+142%) of
the latter is easily explained by a very anarchical and overuse
of FQ in our country. This overuse could also explain the very
high frequency of FQ-R Neisseria gonorrhoeae. Ampicillin-R
H. influenzae showed very high values, compared to 8.7–
46% range found in other countries [35, 44, 45].
The formula used to identify MDR could explain discrep-
ancies with related specific resistances (MRSA and 3GC-R
Enterobacteriaceae for example), since it included several
antibiotics rather than specific ones. MDR/XDR Acinetobac-
ter spp prevalence was consistent with the worldwide survey
led by Lob in 2016; it ranged from 47% in Northern America
to 93% in Middle East [46]. We found no study from Africa
using the same definition of MDR and XDR for other eligible
pathogens. A local comparison could therefore not be made.
Our study design did not permit to assess what happened
within the 2010–2017 interval. Therefore, real trends could
be different from what our results assumed. The retrospective
enrollment led to a huge number of excluded specimen and
missing data, increasing risk of information bias. Data on
providing patients were insufficient, making clinical corre-
lation impossible and population profile nonassessable.
However, the accessibility and affordability of CPC allow
inclusion of patients from different regions and social cate-
gories. Every citizen can realize tests in CPC, and discounts
up to 50% are applied for students, children, the elderly,
civilian servants, and hospitalized patients from public hos-
pitals. Whole-year enrollment was an advantage since it
allowed to overcome potential between-season variations
in circulating pathogens. This study succeeded in informing
one of the WHO action plan’s objectives, especially with
the assessment of WHO priority resistances. Using data
from a reference laboratory with cutting-edge equipment
was a quality guarantee.
Taking into consideration, these AMR’s prevalence may
help Cameroonian clinicians in their daily practice, given
that very few health facilities all around the country can
attend a proper bacteriologic test. High prevalence of serious
resistances could encourage decision-makers to build pro-
grams addressing AMR in the country. They could also be
used to sensitize health workers and medical students on
the reality of this phenomenon in the country and support
training on this important issue.
Clinical data related to identify bacteria could not be
reached. Prospective designs should overcome this limita-
tion. The real dynamic of AMR evolution could not be
assessed in this study, but trends have been revealed.
Repeated similar studies or cohorts would be needed to have
a long-term evolution. Extrapolation of these results to the
whole country should be cautious, and local or regional stud-
ies would be necessary to complete them. Circulating bacteria
are not limited to humans and patients; environment and
animals must be studied as well.
5. Conclusion
In this study designed to assess AMR trends in Cameroon,
most of bacteria of clinical interest have shown high resis-
tance rates, which increased between 2010 and 2017, espe-
cially WHO priority pathogens. Almost all the strains
identified had an acquired resistance. The prevalence of
MDR was high, while XDR remained low but increased,
and PDR was absent. These results contributed to improve
knowledge on AMR in Cameroon and advocate for an urgent
need of public health strategies against this threat. There is a
need for regular surveillance of antibacterial resistance to
keep decision-makers and clinicians informed.
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